403 related articles for article (PubMed ID: 7925608)
1. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
2. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
3. Photoaffinity labelling of cyclic GMP-binding proteins in human platelets.
Tang KM; Sherwood JL; Haslam RJ
Biochem J; 1993 Sep; 294 ( Pt 2)(Pt 2):329-33. PubMed ID: 8396909
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
5. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
6. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
7. A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5).
Corbin JD; Beasley A; Turko IV; Haik TL; Mangum KA; Wells JN; Francis SH; Sekhar KR
Cell Biochem Biophys; 1998; 29(1-2):145-57. PubMed ID: 9631243
[TBL] [Abstract][Full Text] [Related]
8. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
9. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
Lugnier C; Schini VB
Biochem Pharmacol; 1990 Jan; 39(1):75-84. PubMed ID: 2153383
[TBL] [Abstract][Full Text] [Related]
11. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
12. Effects of hepatocyte growth factor on cyclic nucleotide-dependent signaling and steroidogenesis in rat ovarian granulosa cells in vitro.
Zachow RJ; Woolery JK
Biol Reprod; 2002 Aug; 67(2):454-9. PubMed ID: 12135881
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
14. Absence of an effect of the lithium-induced increase in cyclic GMP on the cyclic GMP-stimulated phosphodiesterase (PDE II). Evidence for cyclic AMP-specific hydrolysis.
Harvey B; Carstens M; Taljaard J
Neurochem Res; 1993 Oct; 18(10):1095-100. PubMed ID: 8255358
[TBL] [Abstract][Full Text] [Related]
15. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.
Souness JE; Brazdil R; Diocee BK; Jordan R
Br J Pharmacol; 1989 Nov; 98(3):725-34. PubMed ID: 2480168
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
18. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
19. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
Torphy TJ; Cieslinski LB
Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
[TBL] [Abstract][Full Text] [Related]
20. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]